Lexeo Therapeutics
Develops genetic medicines for inherited cardiovascular disease and select CNS disorders.
Something off on this page? Send us feedback.
Profile
Focused on pre-commercial AAV gene therapies, with lead work in Friedreich ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy. The business depends on clinical success, regulatory approval, manufacturing readiness, and eventual commercialization.
Develops investigational AAV gene therapies for genetically defined cardiovascular diseases and a smaller CNS program. Lead candidate LX2006 delivers a functional FXN gene for Friedreich ataxia cardiomyopathy, while LX2020 targets PKP2-associated arrhythmogenic cardiomyopathy.
Earlier cardiac work includes LX2021 for desmoplakin cardiomyopathy and LX2022 for TNNI3-associated hypertrophic cardiomyopathy. LX1020 applies APOE2 delivery and APOE4 suppression in an APOE4-associated Alzheimer's disease program.
Retains exclusive worldwide development and commercialization rights to its candidates, with operations run from New York and a clinical-development-heavy workforce. The business depends on completing trials, obtaining approval, manufacturing readiness, and commercialization.
Company facts
Key statistics
Year to date −49.4% · Average volume (30d) 977.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jan 13, 2026 | H.C. Wainwright | Target | $13 | $10 | |
| Dec 17, 2025 | Raymond James | Target | $25 | ||
| Dec 10, 2025 | Oppenheimer | Target | $20 | ||
| Nov 20, 2025 | Cantor Fitzgerald | Target | $19 | ||
| Oct 21, 2025 | H.C. Wainwright | Target | $15 | $13 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.30 | −$0.30 | 0.0% | — | — | — | +1.85% |
| Aug 12, 2026Q2 FY26 | −$0.29 | −$0.30 | −5.2% | — | — | — | +1.88% |
| May 11, 2026Q1 FY26 | −$0.29 | −$0.25 | +13.8% | — | — | — | −6.86% |
| Mar 30, 2026Q4 FY25 | −$0.32 | −$0.27 | +15.6% | — | — | — | +8.92% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$546.0K | $0 | |
| Operating income | −$33.8M | −$30.7M | −$21.6M | −$23.1M | −$22.3M | −$28.0M | |
| Net income | −$32.7M | −$26.1M | −$20.3M | −$20.9M | −$20.2M | −$25.9M | |
| Diluted EPS | −$0.99 | −$0.60 | −$0.33 | −$0.27 | −$0.25 | −$0.30 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY22 $653.6K · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $211.7M · Total debt $6.8M · Total assets $254.9M · Shareholders' equity $235.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 78.52M · Float 47.42M · 60.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Balyasny Asset Management L.P. | 7.18M | 9.69% | 13G | May 15, 2026 |
| Paradigm BioCapital Advisors LP | 6.18M | 8.30% | 13G | May 15, 2026 |
| Suvretta Capital Management, LLC | 5.67M | 7.70% | 13G | Apr 13, 2026 |
| BlackRock, Inc. | 5.11M | 6.51% | 13F | May 13, 2026 |
| Affinity Asset Advisors, LLC | 5.05M | 6.43% | 13F | May 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Jose Manuel Otero | officer: Chief Operating Officer | −1,304 | $4.96 |
| Aug 18, 2026 | Richard Nolan Townsend | director, officer: Chief Executive Officer | −3,345 | $4.95 |
| Aug 18, 2026 | Louis Edward Tamayo | officer: Chief Financial Officer | −4,117 | $4.91 |
| Jul 1, 2026 | Richard Nolan Townsend | director, officer: Chief Executive Officer | −25,947 | $4.48 |
| Jul 1, 2026 | Narinder Pal Bhalla | officer: Chief Medical Officer | −22,306 | $4.42 |
Peers
- Rocket Pharmaceuticals
AAV cardiovascular gene therapy peer in PKP2, Danon, and BAG3 programs
- Tenaya Therapeutics
Cardiac gene therapy peer with PKP2 and MYBPC3 cardiomyopathy programs
- Solid Biosciences
FA and cardiac genetic-medicine pipeline using AAV gene therapy
- Voyager Therapeutics
FXN gene-replacement program for Friedreich ataxia with Neurocrine
- Biogen
Approved Friedreich ataxia therapy owner through SKYCLARYS
- Intellia Therapeutics
One-time in vivo gene editing program for ATTR cardiomyopathy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics | $4.77 | −1.95% | $381.6M | — | — | — | — |
| Rocket Pharmaceuticals | $3.82 | −0.91% | $421.5M | — | — | — | — |
| Tenaya Therapeutics | $0.6956 | +0.40% | $149.8M | — | — | 112.2 | — |
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| Voyager Therapeutics | $3.53 | −0.28% | $213.9M | — | — | 6.2 | −39.1% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Median | 38.7 | 16.5 | 18.2 | −39.1% |